We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

113 hedge funds and large institutions have $623M invested in Relmada Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

97% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $13.4M

95% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 21

33% more capital invested

Capital invested by funds: $467M → $623M (+$156M)

16% more funds holding

Funds holding: 97 → 113 (+16)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

39.73% less ownership

Funds ownership: 118.31% → 78.58% (-40%)

Holders
113
Holders Change
+16
Holders Change %
+16.49%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
29
Increased
41
Reduced
21
Closed
13
Calls
$26.4M
Puts
$13.4M
Net Calls
+$13M
Net Calls Change
+$10.4M

Top Buyers

1
CAC
Cowen and Company
New York
+$21M
2
Citadel Advisors
Citadel Advisors
Florida
+$13.3M
3
BlackRock
BlackRock
New York
+$11.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.57M
5
RI
RTW Investments
New York
+$7.31M

Top Sellers

1
APM
Avidity Partners Management
Texas
-$16.5M
2
LGM
Logos Global Management
California
-$9.01M
3
Morgan Stanley
Morgan Stanley
New York
-$6.35M
4
Millennium Management
Millennium Management
New York
-$5.67M
5
SFM
Sphera Funds Management
Israel
-$3.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
HS
51
HighVista Strategies
Massachusetts
$577K +$442K +21,381 New
State of Wisconsin Investment Board
52
State of Wisconsin Investment Board
Wisconsin
$564K +$432K +20,900 New
PPA
53
Parametric Portfolio Associates
Washington
$529K +$406K +19,618 New
CCM
54
Cinctive Capital Management
New York
$518K +$397K +19,200 New
AllianceBernstein
55
AllianceBernstein
Tennessee
$483K – – –
CS
56
Credit Suisse
Switzerland
$478K +$140K +6,789 +62%
BG
57
Bellevue Group
Switzerland
$432K +$331K +16,000 New
JP Morgan Chase
58
JP Morgan Chase
New York
$427K +$174K +8,426 +113%
CM
59
CM Management
Florida
$405K +$103K +5,000 +50%
PVI
60
Pura Vida Investments
New York
$402K +$2.07K +100 +0.7%
WIA
61
World Investment Advisors
California
$383K – – –
MIM
62
MetLife Investment Management
New Jersey
$380K +$152K +7,337 +109%
Manulife (Manufacturers Life Insurance)
63
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$379K +$294K +14,206 New
MAM
64
Martingale Asset Management
Massachusetts
$374K -$76.5K -3,700 -21%
New York State Common Retirement Fund
65
New York State Common Retirement Fund
New York
$352K – – –
JG
66
Jefferies Group
New York
$335K +$257K +12,428 New
GSEP
67
Golden State Equity Partners
California
$334K +$1.03K +50 +0.4%
AIG
68
American International Group
New York
$333K +$83K +4,012 +48%
D.E. Shaw & Co
69
D.E. Shaw & Co
New York
$283K +$217K +10,487 New
Two Sigma Investments
70
Two Sigma Investments
New York
$283K +$217K +10,500 New
CG
71
Cutler Group
California
$263K +$197K +9,546 +4,773%
Invesco
72
Invesco
Georgia
$247K +$189K +9,122 New
HSBC Holdings
73
HSBC Holdings
United Kingdom
$247K +$192K +9,275 New
VEA
74
Virtus ETF Advisers
New York
$230K -$10.3K -499 -6%
TD Asset Management
75
TD Asset Management
Ontario, Canada
$228K +$175K +8,455 New
1 2
3
4 5

RLMD Hedge Fund Activity: Q1 2022 in Review

113 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2022, worth a combined $623M — up 33% from $467M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RLMD positions and 13 closed out — a net gain of 16 holders — while 41 added to existing stakes and 21 trimmed.

The largest buyer was Cowen and Company, adding an estimated $21M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $16.5M sold.

  • 113 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2022, up from 97 in Q4 2021.
  • Funds reported $623M of Relmada Therapeutics stock for Q1 2022, up 33% quarter-over-quarter.
  • 29 funds opened new Relmada Therapeutics positions in Q1 2022 and 13 closed out, a net change of +16 holders.
  • The largest Relmada Therapeutics buyer in Q1 2022 was Cowen and Company, an estimated $21M added.
  • The largest Relmada Therapeutics seller in Q1 2022 was Avidity Partners Management, an estimated $16.5M sold.

Based on aggregated 13F filings for Q1 2022.